Astellas makes first filing for darexaban, for orthopaedic use
This article was originally published in Scrip
Executive Summary
Astellas has filed the first approval application worldwide for its oral Factor Xa inhibitor darexaban maleate (YM150), in Japan for the prevention of venous thromboembolism (VTE) in at-risk patients, such as those undergoing major orthopaedic surgery of the lower limbs.